A practical reference on actin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-18 and is reviewed periodically as new material appears.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
The layer lining the medullary cavity of both specimens likely represent endosteal bone deposition, during which new bone matrix is deposited on the inner surface of the cortical bone. The authors also described a partial dentary (FMNH PR 4920) from the Hell Creek Formation and isolated teeth from the Lance Formation as hatchling T. rex and interpret their tooth wear as evidence of consuming relatively large vertebrates. The body length and body mass of the hatchling T. rex (RSKM P2416.82) are estimated to be approximately 75 cm (2.46 ft) and 2.5 kg (5.5 lb) respectively, and those of the hatchling cf. G. libratus (TMP 1981.16.475) are estimated to be approximately 70 cm (2.3 ft) and 2.4 kg (5.3 lb) respectively. On the basis of these body size estimates, Longrich et al. (2026) suggested that the clutch of the confirmed, reproductively mature female T. rex (MOR 1125) would have weighed at least 54–60 kg (119–132 lb) which would possibly correspond to 21-32 eggs. They further stated that larger clutch sizes are also plausible, indicating that tyrannosaurids possibly employed R-selection, a reproductive strategy that maximizes the number of offsprings through large clutch size and minimal parental investment, which would have resulted in rapid maturation of the hatchlings, slower than that of modern birds. It is also likely that the reproduction strategy of tyrannosaurids was an intermediate between R-selection and K-selection, the latter of which would maximize parental investment with fewer number of offsprings and delayed maturation.
MacKinnon, Charlotte M.; Carter, Philip E.; Smyth, S. Jane; Dunbar, Bryan; Fothergill, John E. (1987). "Molecular cloning of cDNA for human complement component C1s. The complete amino acid sequence". European Journal of Biochemistry. 169 (3): 547–553. doi:10.1111/j.1432-1033.1987.tb13644.x. PMID 3500856. Snoke, JE; Yanari, S; Bloch, K (1953). "Synthesis of glutathione from gamma-glutamylcysteine". The Journal of Biological Chemistry. 201 (2): 573–586. doi:10.1016/S0021-9258(18)66212-X. PMID 13061393. Mandeles, S; Block, K (1955). "Enzymatic synthesis of gamma-glutamylcysteine". The Journal of Biological Chemistry. 214 (2): 639–646. doi:10.1016/S0021-9258(18)70912-5. PMID 14381401.
== Uses == Gamma-Butyrolactone is used as a chemical solvent and a cleaning agent, for example in paint stripping or for cleaning graffiti. Butyrolactone is a precursor to other chemicals. Reaction with methylamine gives NMP, and with ammonia gives pyrrolidone. It is also used as a solvent in lotions and some polymers.
== Publication history == Mogo first appeared in Green Lantern (vol. 2) #188 (May 1985) in a story titled "Mogo Doesn't Socialize" and was created by writer Alan Moore and artist Dave Gibbons. Although initially a one-off character from a short story, the planet has grown in importance in the Green Lantern mythos and is a necessary part of the process for distributing power rings as well as a destination for Corps members to recuperate.
Sources: en.wikipedia.org
== Receptors == The studies cited above lead to the eventual cloning of the human Formyl peptide receptor 1, a G protein coupled receptor that binds fMLF and other formylated oligopeptides to mediate their stimulatory actions on human and rabbit neutrophils. Subsequently, Formyl peptide receptor 2 and Formyl peptide receptor 3 were also cloned based on the similarities in their amino acid sequence to that of formyl peptide receptor 1. Formyl peptide receptors 2 and 3 have very different abilities to bind and respond to formylated oligopeptides including fMLF compared to formyl peptide receptor 1 and compared to each other and have very different functions than those of formyl peptide receptor 1.
By the early modern period, Neo-Latin had become the lingua franca of science, medicine, legal discourse, theology, and education in Europe. Over time, the use of Latin continued where international communication with specialist audiences was paramount. Later, where some of the discourse moved to French, English or German, translations into Latin would allow texts to cross language boundaries, while authors in countries with much smaller language populations or less known languages would tend to continue to compose in Latin. Latin's dominance over medicine began to change in the late seventeenth century, as philosophers and others began to write in their native language first, afterwards translating into Latin for international audiences. In the early part of the 1700s, Latin was still making a significant contribution to academic publishing, but was no longer dominant. Examples of modern medical dictionaries include Mosby's Dictionary of Medicine, Nursing & Health Professions, Stedman's, Taber's, and Dorland's.
=== Applications in semiconductor industry === UPW is used extensively in the semiconductor industry where the highest grade of purity is required. The use of UPW varies; it may be used to rinse the wafer after application of chemicals, to dilute the chemicals themselves, in optics systems for immersion photolithography, or as make-up to cooling fluid in some critical applications. UPW is even sometimes used as a humidification source for the cleanroom environment. The primary, and most critical, application of UPW is in wafer cleaning in and after wet etching step during the FEOL stage. Impurities which can cause product contamination or impact process efficiency (e.g. etch rate) must be removed from the water during cleaning and etching stage. In chemical-mechanical polishing processes, water is used in addition to reagents and abrasive particles. As of 2002 1-2 parts of contaminating molecules per one million of water ones was considered to be an "ultrapure water" (e.g. semiconductor grade).
== Further reading == Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. Administration of radioactive substances advisory committee. March 2006. Produced by the Health Protection Agency. Malabsorption. In: The Merck Manual of Geriatrics, chapter 111. Leukoscan summary of product characteristics (Tc99m-Sulesomab). Schwochau, Klaus. Technetium. Wiley-VCH (2000). ISBN 3-527-29496-1
==== Increased throughput ==== While DMF systems cannot match the same throughput achieved by some liquid handling pipetting robots, or by some droplet-based microfluidic systems, there are still throughput advantages when compared to conventional methods carried out manually.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.